Thursday, Nov. 7, 2019
8 a.m. – 5 p.m.
Program Purpose
The understanding of cancer immunobiology has increased dramatically in recent years, leading to the successful development of novel immune-based treatment options to improve cancer patient outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer.
Intended Audience
The intended audience for this annual, one-day educational program includes students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy, pharmacists, and registered nurses.
Primer Organizers
- Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
- Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Educational Objectives
Upon completion of this meeting, participants will be able to:
- Describe the key principles of tumor immunology and immunotherapy
- Summarize the basic principles of passive immunotherapy, in which antibodies or T lymphocytes generated outside of the patient are administered with therapeutic intent
- Discuss the techniques involved in active immunotherapy, including tumor antigen vaccination as well as immune checkpoint blockade
- Outline immune monitoring techniques, both in peripheral blood and sera, as well as in patient samples collected in pre-surgical trials
- Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer
SITC's Primer on Tumor Immunology and Cancer Immunotherapy™ is supported in part by grants from Bristol-Myers Squibb, Celgene Corporation, Genentech, Merck & Co., Inc. and Pfizer, Inc. (as of Sept. 27, 2019)
Program Schedule
|
Thursday, Nov. 7, 2019
|
|
|
8 a.m.
|
Introduction
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
|
|
Session 1: Tumor Immunity I
|
|
Time:
|
8:05 – 9:55 a.m.
|
|
8:05 a.m.
|
The Adaptive Immune Response
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
|
|
8:35 a.m.
|
Macrophages, Dendritic and Myeloid Cells
Tyler Curiel, MD – UT Health San Antonio
|
|
9:05 a.m.
|
Harnessing Natural Killer Cells and Innate Lymphoid Cells to Potentiate Antitumor Immunity
Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai
|
|
9:35 a.m.
|
Tumor Immunity I Panel Discussion
Moderator:
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center
Panelists:
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai
Tyler Curiel, MD – UT Health San Antonio
|
|
9:55 a.m.
|
Break
|
|
Session 2: Tumor Immunity II
|
|
Time:
|
10:10 a.m. – 12 p.m. |
|
10:10 a.m.
|
Regulation of Cancer Immunity by Metabolic and Microbiome Interactions
Greg Delgoffe, PhD – University of Pittsburgh
|
|
10:40 a.m.
|
Redefining Cancer Vaccination
Tanja de Gruijl, PhD – VU University Medical Center
|
|
11:10 a.m.
|
Monoclonal Antibodies and Their Derivatives
Charles G. Drake, MD, PhD – Columbia University
|
|
11:40 a.m.
|
Tumor Immunity II Panel Discussion
Moderator:
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Panelists:
Tanja de Gruijl, PhD – VU University Medical Center
Greg Delgoffe, PhD – University of Pittsburgh
Charles G. Drake, MD, PhD – Columbia University
|
|
12 p.m.
|
Lunch |
|
Session 3: Analysis of Resistance and Response
|
|
Time:
|
1 – 2:55 p.m. |
|
1 p.m.
|
Introduction
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center
|
|
1:05 p.m.
|
Extrinsic Mechanisms of Resistance: A Miserable Microenvironment
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center
|
|
1:35 p.m.
|
Checkpoint Receptors - Pathways to Resistance
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
|
|
2:05 p.m.
|
Correlative High-Dimensional Analyses in Cancer Immunotherapy: From Infrastructure to Assays to Useful Predictive Biomarkers
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai
|
|
2:35 p.m.
|
Analysis of Resistance and Response Panel Discussion
Moderator:
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Panelists:
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai
|
|
2:55 p.m.
|
Break
|
|
Session 4: Current IO Immunotherapy
|
|
Time:
|
3:10 – 4:55 p.m. |
|
3:10 p.m.
|
Adoptive T Cell Therapy
Patrick Hwu, MD – University of Texas MD Anderson Cancer Center
|
|
3:40 p.m.
|
Combination Immunotherapies
Leisha Emens, MD, PhD – University of Pittsburgh
|
|
4:10 p.m.
|
Diagnosis, Management and Mechanisms of Immune-related Adverse Events
Jarushka Naidoo, M.B.B.Ch – Johns Hopkins Medicine
|
|
4:40 p.m.
|
Current IO Immunotherapy Panel Discussion
Moderator:
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center
Panelists:
Leisha Emens, MD, PhD – University of Pittsburgh
Patrick Hwu, MD – University of Texas MD Anderson Cancer Center
Jarushka Naidoo, M.B.B.Ch – Johns Hopkins Medicine
|
|
4:55 p.m.
|
Closing
|
|
5 p.m.
|
Adjourn
|